Jnana Therapeutics

Acquired

Jnana Therapeutics is a biotech company in Boston, United States, founded in 2017. It has raised $207.0M across 3 rounds, most recently a $107.0M Series C in November 2022.

Enlightened innovation. Expansive therapeutic impact.

Employees
51–200
Founded
2017
Business Model
B2B
Total Funding
$207.0M
Last Round
$107.0M Series CNov 2022
Rounds
3
Acquisition Date
Aug 2024

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 3 funding rounds and 7 investors for this company. The full record is or through the API.

About

Jnana Therapeutics is a clinical-stage biotechnology company founded in 2017 and headquartered in Boston, Massachusetts, that leverages its proprietary RAPID chemoproteomics platform to discover small molecule medicines for rare genetic metabolic and immune-mediated diseases. The RAPID platform enables systematic identification of unique binding sites on highly validated but historically hard-to-drug protein targets, dramatically accelerating the path from target to clinical candidate. Jnana's lead program, JNT-517, is an oral allosteric inhibitor targeting phenylketonuria (PKU), a serious inherited metabolic disorder; in 2024 the company was acquired by Otsuka Pharmaceutical for approximately $800 million, becoming a subsidiary of Otsuka America.

Summary

It lists 51–200 employees. It has raised $207.0M in total across 3 rounds, most recently a $107.0M Series C round in Nov 2022. Investors include RA Capital Management, Polaris Partners and Bain Capital Life Sciences.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionAcquisition by Otsuka PharmaceuticalAug 2024

Sign up to see all 4 events

Funding: Series A through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Jnana Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/jnana-therapeutics"><img src="https://indexed.vc/api/badge/company/jnana-therapeutics" alt="Jnana Therapeutics on Indexed.vc" width="260" height="76" /></a>